RxDoctor Payments Data

Amir Salim, MD

Family Medicine · Webster, TXNPI 1619901006

Payments from drug & device makers

$30,389in general payments, 2019–2025

Across 1,280 payments — averaging $23.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$6K
  • Novo Nordisk$3K
  • AbbVie$2K
  • Amarin Pharma, Inc.$2K
  • Lilly USA, LLC$2K
  • Bayer$1K
  • plus $14K from 54 others

What the payments were for

  • Consulting fees$1,2004%
  • Speaking & faculty fees$160%
  • Food & beverage$28,60494%
  • Education$5692%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca155$5,616
Novo Nordisk88$2,645
AbbVie(2 entities)136$2,493
Amarin Pharma, Inc.187$2,422
Lilly USA, LLC104$1,668
Bayer52$1,444
Amgen(2 entities)54$1,407
GSK60$1,285
Biohaven Pharmaceuticals, Inc.5$1,271
Axsome Therapeutics, Inc.18$785
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)30$736
Pfizer24$666
Boehringer Ingelheim23$620
Merz North America, Inc.8$614
Astellas Pharma US Inc14$565
Esperion Therapeutics, Inc.22$563
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC27$535
Antares Pharma, Inc.34$473
Takeda Pharmaceuticals U.S.A., Inc.17$438
Phathom Pharmaceuticals, Inc.4$351
Novartis18$325
Eisai Inc.17$323
Abbott17$310
Kowa Pharmaceuticals America, Inc.18$294
Merck22$272
Sanofi-aventis U.S. LLC11$180
Corium, LLC15$176
Teva Pharmaceuticals USA, Inc.9$166
Exact Sciences8$137
Inspire Medical Systems, Inc.1$123
Idorsia Pharmaceuticals US Inc7$114
Genentech USA, Inc.5$104
Paratek Pharmaceuticals, Inc.4$78
Adlon Therapeutics L.p.4$77
Acella Pharmaceuticals, LLC4$74
Corcept Therapeutics3$66
Supernus Pharmaceuticals, Inc.3$62
Noven Therapeutics, LLC3$62
Vertex2$61
Otsuka America Pharmaceutical, Inc.3$59
Acerus Pharmaceuticals Corporation4$57
Azurity Pharmaceuticals, Inc.3$49
ARS Pharmaceuticals Operations, Inc.2$48
Xeris Pharmaceuticals, Inc.3$45
Ironshore Pharmaceuticals Inc.2$44
Halozyme Inc2$41
Nestle Healthcare Nutrition Inc.2$41
Revance Therapeutics, Inc.2$39
Gilead2$38
Shire North American Group Inc2$35
Currax Pharmaceuticals LLC2$33
Althera Pharmaceuticals LLC4$25
Johnson & Johnson1$23
Tolmar, Inc.1$21
Hikma Pharmaceuticals USA1$19
Seqirus USA Inc1$19
Vertical Pharmaceuticals, LLC1$18
Zyla Life Sciences, Inc.1$17
Medicure Pharma Inc.1$16
Avion Pharmaceuticals1$16

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$30,389 in reported general payments places this provider in the 95th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$219,229
Medicare patients
226
Services billed
3,556

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide152$149,198
FarxigaDapagliflozin Propanediol128$137,596
MounjaroTirzepatide48$51,833
TrulicityDulaglutide20$27,215
MyrbetriqMirabegron22$26,967
JanuviaSitagliptin Phosphate18$24,614
Trelegy ElliptaFluticasone/Umeclidin/Vilanter27$20,532
Xigduo XrDapaglifloz Propaned/Metformin26$15,210
VascepaIcosapent Ethyl16$13,357
RybelsusSemaglutide11$11,997
Icosapent Ethyl31$11,905
JardianceEmpagliflozin16$10,188
XyostedTestosterone Enanthate12$6,627
Liothyronine Sodium80$6,478
Ezetimibe201$4,308

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$2,645$161,195163 claims
AstraZenecaFarxiga$5,616$137,596128 claims
Lilly USA, LLCMounjaro, Trulicity$1,668$79,04868 claims
Astellas Pharma US IncMyrbetriq$565$26,96722 claims
MerckJanuvia$272$24,61418 claims
GSKTrelegy Ellipta, Breo Ellipta$1,285$24,00338 claims
Boehringer IngelheimJardiance$620$10,18816 claims
Antares Pharma, Inc.Xyosted$473$6,62712 claims
AbbVieSynthroid$2,493$3,17634 claims
Acella Pharmaceuticals, LLCNp Thyroid$74$1,43821 claims
PfizerPaxlovid$666$1,42914 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Webster

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →